Prevention versus cure: Is BioGlue priming the optimal strategy against E-Vita NEO graft oozing?

Sven Zhen Cian Patrick Tan Mohammad Bashir

Published in: Journal of cardiac surgery (2021)

Graft oozing from E-Vita Open NEO represents an omnipresent and worrying risk. The use of BioGlue herein is likely associated with several adverse consequences, which are an additional risk on top of that posed by graft oozing. These risks call into question the suitability of E-Vita Open NEO, especially when compared to alternative devices not affected by oozing.

Keyphrases

minimally invasive
emergency department
human health
risk assessment
adverse drug
electronic health record